Literature DB >> 25288231

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.

Rebecca Roylance1, David Endesfelder, Mariam Jamal-Hanjani, Rebecca A Burrell, Patricia Gorman, Jil Sander, Niamh Murphy, Nicolai Juul Birkbak, Andrew M Hanby, Valerie Speirs, Stephen R D Johnston, Maik Kschischo, Charles Swanton.   

Abstract

Regulators of transition through mitosis such as SURVIVIN and Aurora kinase A (AURKA) have been previously implicated in the initiation of chromosomal instability (CIN), a driver of intratumour heterogeneity. We investigate the relationship between protein expression of these genes and directly quantified CIN, and their prognostic utility in breast cancer. The expression of SURVIVIN and AURKA was determined by immunohistochemistry in a cohort of 426 patients with primary breast cancer. The association between protein expression and histopathological characteristics, clinical outcome and CIN status, as determined by centromeric FISH and defined by modal centromere deviation, was analysed. Significantly poorer clinical outcome was observed in patients with high AURKA expression levels. Expression of SURVIVIN was elevated in ER-negative relative to ER-positive breast cancer. Both AURKA and SURVIVIN increased expression were significantly associated with breast cancer grade. There was a significant association between increased CIN and both increased AURKA and SURVIVIN expression. AURKA gene amplification was also associated with increased CIN. To our knowledge this is the largest study assessing CIN status in parallel with the expression of the mitotic regulators AURKA and SURVIVIN. These data suggest that elevated expression of AURKA and SURVIVIN, together with AURKA gene amplification, are associated with increased CIN in breast cancer, and may be used as a proxy for CIN in breast cancer samples in the absence of more advanced molecular measurements.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25288231     DOI: 10.1007/s10549-014-3153-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis.

Authors:  M Kamran; Z-J Long; D Xu; S-S Lv; B Liu; C-L Wang; J Xu; E W-F Lam; Q Liu
Journal:  Oncogenesis       Date:  2017-02-20       Impact factor: 7.485

2.  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.

Authors:  Helen Gogas; Vassiliki Kotoula; Zoi Alexopoulou; Christos Christodoulou; Ioannis Kostopoulos; Mattheos Bobos; Georgia Raptou; Elpida Charalambous; Eleftheria Tsolaki; Ioannis Xanthakis; George Pentheroudakis; Angelos Koutras; Dimitrios Bafaloukos; Pavlos Papakostas; Gerasimos Aravantinos; Amanda Psyrri; Kalliopi Petraki; Konstantine T Kalogeras; Dimitrios Pectasides; George Fountzilas
Journal:  J Transl Med       Date:  2016-05-17       Impact factor: 5.531

Review 3.  Aurora-A Kinase as a Promising Therapeutic Target in Cancer.

Authors:  Antonino B D'Assoro; Tufia Haddad; Evanthia Galanis
Journal:  Front Oncol       Date:  2016-01-06       Impact factor: 6.244

4.  Identification of potential core genes in triple negative breast cancer using bioinformatics analysis.

Authors:  Man-Xiu Li; Li-Ting Jin; Tie-Jun Wang; Yao-Jun Feng; Cui-Ping Pan; Dei-Mian Zhao; Jun Shao
Journal:  Onco Targets Ther       Date:  2018-07-18       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.